Key result
Corticosteroids are recommended as an effective adjunctive treatment for Kawasaki disease, particularly as rescue therapy for immunoglobulin-resistant cases or initial therapy in high-risk patients.
Why the study?
The timing and role of corticosteroid treatment in Kawasaki disease have been widely discussed, particularly regarding its efficacy in specific populations such as high-risk patients.
Do corticosteroids improve outcomes in pediatric patients with Kawasaki disease?
Do corticosteroids improve outcomes in pediatric patients with Kawasaki disease?
Corticosteroids, particularly methylprednisolone pulse therapy, are recommended as an effective adjunctive treatment for high-risk or immunoglobulin-resistant Kawasaki disease.
Supports adjunctive corticosteroids in high-risk or resistant Kawasaki disease; leaves open need for confirmatory randomized trials.
Introduction: Kawasaki disease (KD) is a form of systemic vasculitis that can lead to complications of coronary artery lesions (CAL). Diagnosis without delay and treatment with intravenous immunoglobulin (IVIG) are vital for a better prognosis. Anti-inflammatory drugs are generally used empirically in pediatric patients as off label. Corticosteroids are effective with anti-inflammatory effects applied in vasculitis.Areas covered: The timing of corticosteroid treatment in KD has been widely discussed by scholars. Some corticosteroids may still be effective which could be useful for such specific populations as high-risk patients. In this narrative review, we searched clinical studies, meta-analyzes, and systemic reviews using the PubMed database to summarize the available evidence on corticosteroid usage in KD through October 2019 and then discussed the relevant issues.Expert opinion: Today, the available evidence is more powerful to recommend corticosteroids for KD, moving from an unproven therapy to an effective adjunctive treatment. We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration. In the future, studies that evaluate the precision role of corticosteroids for individualized KD patients with CAL are warranted.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2020) conducted a review in Kawasaki disease. Corticosteroids was evaluated. Corticosteroids are recommended as an effective adjunctive treatment for Kawasaki disease, particularly as rescue therapy for immunoglobulin-resistant cases or initial therapy in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: